BMRN Q4 2019 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$454M+28.7% YoY

Gross Profit

$359M78.9% margin

Operating Income

-$9M-2.0% margin

Net Income

$15M3.3% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

$57M

Free Cash Flow

$7M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4.7B

Total Liabilities

$1.6B

Stockholders' Equity

$3.1B

Cash & Equivalents

$437M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$454M	$353M	+28.7%
Gross Profit	$359M	$278M	+28.9%
Operating Income	-$9M	-$38M	+76.0%
Net Income	$15M	-$4M	+511.6%

Revenue Segments

Product

$437M50%

Product Four

$132M15%

Product Three

$123M14%

Product Two

$95M11%

Product Seven

$32M4%

Product Six

$25M3%

Royalty And Other

$18M2%

Product Five

$6M1%

Geographic Segments

UNITED STATES

$216M48%

Europe

$140M31%

Latin America

$55M12%

Rest Of World

$44M10%